Department of Endocrinology, Diabetes and Nutrition, CHU of Bordeaux and University of Bordeaux, Pessac, France.
Endocrinology Department, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER, Unidad 747) Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.
Front Endocrinol (Lausanne). 2022 Aug 8;13:934347. doi: 10.3389/fendo.2022.934347. eCollection 2022.
Impaired cognition and altered quality of life (QoL) may persist despite long-term remission of Cushing's disease (CD). Persistent comorbidities and treatment modalities may account for cognitive impairments. Therefore, the role of hypercortisolism on cognitive sequelae remains debatable.
To investigate whether memory and QoL are impaired after long-term remission of CD in patients with no confounding comorbidity.
Cross-sectional case-control study in two tertiary referral centers.
25 patients (44.5 ± 2.4 years) in remission from CD for 102.7 ± 19.3 Mo and 25 well-matched controls, without comorbidity or treatment liable to impair cognition.
Hippocampus- and prefrontal cortex-dependent memory, including memory flexibility and working memory, were investigated using multiple tests including sensitive locally-developed computerized tasks. Depression and anxiety were evaluated with the MADRS and HADS questionnaires. QoL was evaluated with the SF-36 and CushingQoL questionnaires. The intensity of CD was assessed using mean urinary free cortisol and a score for clinical symptoms.
CD patients displayed similar performance to controls in all cognitive tests. In contrast, despite the absence of depression and a minimal residual clinical Cushing score, patients had worse QoL. Most of the SF36 subscales and the CushingQoL score were negatively associated only with the duration of exposure to hypercortisolism (p≤ 0.01 to 0.001).
Persistent comorbidities can be a primary cause of long-lasting cognitive impairment and should be actively treated. Persistently altered QoL may reflect irreversible effects of hypercortisolism, highlighting the need to reduce its duration.
https://clinicaltrials.gov, identifier NCT02603653.
尽管库欣病(CD)长期缓解,认知障碍和生活质量(QoL)改变仍可能持续存在。持续性合并症和治疗方式可能导致认知障碍。因此,皮质醇过多症对认知后遗症的作用仍存在争议。
在没有混杂合并症的 CD 缓解患者中,研究长期缓解后是否存在记忆和 QoL 受损。
在两个三级转诊中心进行的横断面病例对照研究。
25 例缓解 CD 患者(44.5±2.4 岁),缓解时间为 102.7±19.3 个月,25 例匹配良好的对照患者,无合并症或可能损害认知的治疗。
使用包括敏感的本地开发的计算机化测试在内的多项测试,研究海马体和前额叶皮层依赖的记忆,包括记忆灵活性和工作记忆。使用 MADRS 和 HADS 问卷评估抑郁和焦虑。使用 SF-36 和 CushingQoL 问卷评估 QoL。使用平均尿游离皮质醇和临床症状评分评估 CD 严重程度。
CD 患者在所有认知测试中的表现与对照组相似。相比之下,尽管没有抑郁和最小的残留临床库欣评分,患者的 QoL 仍较差。大多数 SF36 子量表和 CushingQoL 评分仅与皮质醇过多暴露时间(p≤0.01 至 0.001)呈负相关。
持续性合并症可能是长期认知障碍的主要原因,应积极治疗。持续改变的 QoL 可能反映皮质醇过多症的不可逆影响,突出了减少其持续时间的必要性。
https://clinicaltrials.gov,标识符 NCT02603653。